Large-cap Health Care company Moderna has logged a 1.4% change today on a trading volume of 8,385,074. The average volume for the stock is 10,680,106.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. Based in Cambridge, United States the company has 5,800 full time employees and a market cap of $11,843,136,512.
The company is now trading -14.3% away from its average analyst target price of $35.37 per share. The 19 analysts following the stock have set target prices ranging from $17.0 to $135.0, and on average give Moderna a rating of hold.
Over the last 12 months MRNA shares have declined by -22.1%, which represents a difference of -37.9% when compared to the S&P 500. The stock's 52 week high is $48.92 per share and its 52 week low is $22.28. Based on Moderna's average net margin growth of 29.0% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 3,236,000 | -3,561,000 | -110 | -59.42 |
| 2023 | 6,848,000 | -4,714,000 | -69 | -260.47 |
| 2022 | 19,263,000 | 8,362,000 | 43 | -34.85 |
| 2021 | 18,471,000 | 12,202,000 | 66 | 170.97 |
| 2020 | 803,000 | -747,000 | -93 | 89.15 |
| 2019 | 60,000 | -514,000 | -857 |
